Gozetotide alf-18
Locametz (gozetotide alf-18) is a small molecule pharmaceutical. Gozetotide alf-18 was first approved as Locametz on 2022-12-09. It has been approved in Europe to treat radionuclide imaging.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| locametz | New Drug Application | 2024-07-09 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| positron-emission tomography | — | D049268 | — |
| radionuclide imaging | — | D011877 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
137 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 26 | 29 | 19 | 5 | 39 | 110 |
| Recurrence | D012008 | — | — | 3 | — | 6 | 1 | 3 | 13 |
| Adenocarcinoma | D000230 | — | — | 2 | 4 | 1 | 1 | 1 | 9 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 3 | 4 | — | 2 | 1 | 8 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | — | — | 2 | — | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatectomy | D011468 | — | — | — | — | 1 | — | — | 1 |
| Radiotherapy | D011878 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 5 | 3 | — | — | 3 | 10 |
| Neoplasms | D009369 | — | C80 | 2 | 5 | — | — | 4 | 10 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 3 | 2 | — | — | 1 | 5 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 2 | — | — | 1 | 5 |
| Triple negative breast neoplasms | D064726 | — | — | — | 2 | — | — | — | 2 |
| Urogenital neoplasms | D014565 | EFO_0003863 | D07 | 1 | 2 | — | — | — | 2 |
| Prostatic diseases | D011469 | — | N42.9 | 1 | 2 | — | — | — | 2 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | 2 | — | — | — | 2 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 2 | — | — | — | 2 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | — | 1 | — | — | 1 | 2 |
Show 7 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Positron emission tomography computed tomography | D000072078 | — | — | 2 | — | — | — | 1 | 3 |
| Neuroendocrine carcinoma | D018278 | — | — | 1 | — | — | — | 2 | 3 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | — | — | — | 1 | 2 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | 1 | 2 |
| Glioma | D005910 | EFO_0000520 | — | 1 | — | — | — | 1 | 2 |
| Lobular carcinoma | D018275 | EFO_0000570 | — | 1 | — | — | — | — | 1 |
| Invasive hydatidiform mole | D002820 | — | D39.2 | 1 | — | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | — | — | — | — | 1 |
Show 7 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | — | — | — | — | 4 | 4 |
| Glioblastoma | D005909 | EFO_0000515 | — | — | — | — | — | 3 | 3 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | — | — | — | — | 1 | 1 |
| Digestive system neoplasms | D004067 | — | — | — | — | — | — | 1 | 1 |
| Papillary thyroid cancer | D000077273 | — | — | — | — | — | — | 1 | 1 |
| Medullary carcinoma | D018276 | — | — | — | — | — | — | 1 | 1 |
| Multiple myeloma | D009101 | — | C90.0 | — | — | — | — | 1 | 1 |
| Plasma cell neoplasms | D054219 | — | — | — | — | — | — | 1 | 1 |
| Urologic neoplasms | D014571 | — | C64-C68 | — | — | — | — | 1 | 1 |
| Sarcoma | D012509 | — | — | — | — | — | — | 1 | 1 |
Show 8 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Gozetotide alf-18 |
| INN | — |
| Description | Locametz (gozetotide alf-18) is a small molecule pharmaceutical. Gozetotide alf-18 was first approved as Locametz on 2022-12-09. It has been approved in Europe to treat radionuclide imaging. |
| Classification | Small molecule |
| Drug class | peptides |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C([O-])CN(CCN(CC(=O)[O-])Cc1cc(CCC(=O)NCCCCCC(=O)NCCCC[C@H](NC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)ccc1O)Cc1cc(CCC(=O)O)ccc1O.[18F-].[Al+3] |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4650355 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 43 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
40 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use